3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Girard, Nicolas ^a,b   Bazille, Céline ^a,b,c   Lhuissier, Eva ^a,b   Benateau, Hervé ^a,b,c   Llombart Bosch, Antonio ^d   Boumediene, Karim ^a,b   Bauge, Catherine ^a,b  

^a NORMANDIE UNIVERSITÉ   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; APO2.7 PROTEIN; CELL PROTEIN; HISTONE H3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; 3-DEAZANEPLANOCIN; ADENOSINE; ENZYME INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE;

APOPTOSIS; ARTICLE; CANCER GRADING; CARTILAGE CELL; CELL ADHESION; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CHONDROSARCOMA; CONTROLLED STUDY; DRUG TARGETING; ENCHONDROMA; EPIGENETICS; FLOW CYTOMETRY; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WOUND HEALING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; ENZYMOLOGY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOSINE; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CHONDROSARCOMA; ENZYME INHIBITORS; FLOW CYTOMETRY; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84901354460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098176     Document Type: Article

References (46)

1. Aloia L, Stefano BD, Croce LD (2013) Polycomb complexes in stem cells and embryonic. Development 140: 2525-2534. doi:10.1242/dev.091553
2. Pereira CF, Piccolo FM, Tsubouchi T, Sauer S, Ryan NK, et al. (2010) ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency. Cell Stem Cell 6: 547-556. doi:10.1016/j.stem.2010.04.013
3. Ding X, Wang X, Sontag S, Qin J, Wanek P, et al. (2013) The Polycomb Protein Ezh2 Impacts on iPS Cell Generation. Stem Cells Dev: 131210220315000. doi:10.1089/scd.2013.0267
4. Fragola G, Germain P-L, Laise P, Cuomo A, Blasimme A, et al. (2013) Cell reprogramming requires silencing of a core subset of polycomb targets. PLoS Genet 9: e1003292. doi:10.1371/journal.pgen.1003292
5. Chen Y-H, Hung M-C, Li L-Y (2012) EZH2: a pivotal regulator in controlling cell differentiation. Am J Transl Res 4: 364-375.
6. Juan AH, Derfoul A, Feng X, Ryall JG, Dell'Orso S, et al. (2011) Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev 25: 789-794. doi:10.1101/gad.2027911
7. Wang L, Jin Q, Lee J-E, Su I, Ge K (2010) Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci U S A 107: 7317-7322. doi:10.1073/pnas.1000031107
8. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629. doi:10.1038/nature01075
9. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani R-S, et al. (2008) Repression of E-cadherin by the Polycomb Group Protein EZH2 in Cancer. Oncogene 27: 7274-7284. doi:10.1038/onc.2008.333
10. Fujii S, Ito K, Ito Y, Ochiai A (2008) Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation. J Biol Chem 283: 17324-17332. doi:10.1074/jbc.M800224200
11. Yu J, Cao Q, Yu J,Wu L, Dallol A, et al. (2010) The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene 29: 5370-5380. doi:10.1038/onc.2010.269
12. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, et al. (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and NF-?B. Nat Med 16: 286-294. doi:10.1038/nm.2100
13. Tan J, Yang X, Zhuang L, Jiang X, Chen W, et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050-1063. doi:10.1101/gad.1524107 (Pubitemid 46686474)
14. Taniguchi H, Jacinto FV, Villanueva A, Fernandez AF, Yamamoto H, et al. (2012) Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene 31: 1988-1994. doi:10.1038/onc.2011.387
15. Chen Y, Xie D, Yin Li W, Man Cheung C, Yao H, et al. (2010) RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett 297: 109-116. doi:10.1016/j.canlet.2010.05.003
16. Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, et al. (2013) Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 23: 997-1005. doi:10.1097/IGC.0b013e318296a265
17. Li H, Cai Q, Godwin AK, Zhang R (2010) Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res MCR 8: 1610-1618. doi:10.1158/1541-7786.MCR-10-0398
18. Ougolkov AV, Bilim VN, Billadeau DD (2008) Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase EZH2. Clin Cancer Res Off J Am Assoc Cancer Res 14: 6790-6796. doi:10.1158/1078-0432. CCR-08-1013
19. Kelly TK, De Carvalho DD, Jones PA (2010) Epigenetic Modifications as Therapeutic Targets. Nat Biotechnol 28. Available: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3022972/. Accessed 2013 December 19.
20. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, et al. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112. doi:10.1038/nature11606
21. Qi W, Chan H, Teng L, Li L, Chuai S, et al. (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 109: 21360-21365. doi:10.1073/pnas.1210371110
22. Wagner T, Jung M (2012) New lysine methyltransferase drug targets in cancer. Nat Biotechnol 30: 622-623. doi:10.1038/nbt.2300
23. Zhao X, Lwin T, Zhang X, Huang A, Wang J, et al. (2013) Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 27: 2341-2350. doi:10.1038/leu.2013.94
24. Crea F, Paolicchi E, Marquez VE, Danesi R (2012) Polycomb genes and cancer: time for clinical application? Crit Rev Oncol Hematol 83: 184-193. doi:10.1016/j.critrevonc.2011.10.007
25. Chase A, Cross NCP (2011) Aberrations of EZH2 in Cancer. Clin Cancer Res 17: 2613-2618. doi:10.1158/1078-0432.CCR-10-2156
26. Cheng LL, Itahana Y, Lei ZD, Chia N-Y, Wu Y, et al. (2012) TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res Off J Am Assoc Cancer Res 18: 4201-4212. doi:10.1158/1078-0432.CCR-12-0036
27. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, et al. (2011) (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 32: 1525-1532. doi:10.1093/carcin/bgr171
28. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, et al. (2011) Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 10: 40. doi:10.1186/1476-4598-10-40
29. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, et al. (2012) EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 31: 753-761. doi:10.1007/s10555-012-9387-3
30. Hayden A, Johnson PWM, Packham G, Crabb SJ (2011) S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anticancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat 127: 109-119. doi:10.1007/s10549-010-0982-0
31. Puppe J, Drost R, Liu X, Joosse SA, Evers B, et al. (2009) BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res BCR 11: R63. doi:10.1186/bcr2354
32. Suvà M-L, Riggi N, Janiszewska M, Radovanovic I, Provero P, et al. (2009) EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance. Cancer Res 69: 9211-9218. doi:10.1158/0008-5472.CAN-09-1622
33. Zhou J, Bi C, Cheong L-L, Mahara S, Liu S-C, et al. (2011) The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118: 2830-2839. doi:10.1182/blood-2010-07-294827
34. Gil-Benso R, Lopez-Gines C, Lopez-Guerrero JA, Carda C, Callaghan RC, et al. (n.d.) Establishment and Characterization of a Continuous Human Chondrosarcoma Cell Line, ch-2879: Comparative Histologic and Genetic Studies with Its Tumor of Origin. Lab Invest 83: 877-887.
35. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif 25: 402-408. doi:10.1006/meth.2001.1262 (Pubitemid 34164012)
36. Duchman KR, Lynch CF, Buckwalter JA, Miller BJ (2014) Estimated Cause-specific Survival Continues to Improve Over Time in Patients With Chondrosarcoma. Clin Orthop. doi:10.1007/s11999-014-3600-3
37. Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, et al. (2013) Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol Off J Eur Soc Med Oncol ESMO 24: 2916-2922. doi:10.1093/annonc/mdt374
38. Angelini A, Guerra G, Mavrogenis AF, Pala E, Picci P, et al. (2012) Clinical outcome of central conventional chondrosarcoma. J Surg Oncol 106: 929-937. doi:10.1002/jso.23173
39. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, et al. (2009) DZNep Is a Global Histone Methylation Inhibitor that Reactivates Developmental Genes Not Silenced by DNA Methylation. Mol Cancer Ther 8: 1579-1588. doi:10.1158/1535- 7163.MCT-09-0013
40. Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, et al. (2012) Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 6: 494-506. doi:10.1016/j.molonc.2012.06.002
41. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol Off J Am Soc Clin Oncol 24: 268-273. doi:10.1200/JCO.2005.01.5180 (Pubitemid 46622055)
42. Mallen-St. Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, et al. (2012) EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 26: 439-444. doi:10.1101/gad.181800.111
43. Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, et al. (2012) 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 130: 2557-2567. doi:10.1002/ijc.26264
44. Fujiwara T, Saitoh H, Inoue A, Kobayashi M, Okitsu Y, et al. (2014) 3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation. J Biol Chem 289: 8121-8134. doi:10.1074/jbc.M114.548651
45. Varier RA, Timmers HTM (2011) Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta BBA - Rev Cancer 1815: 75-89. doi:10.1016/j.bbcan.2010.10.002
46. Hung SW, Mody H, Marrache S, Bhutia YD, Davis F, et al. (2013) Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: In Vitro Optimization and Novel Nanoparticle Delivery Studies. PLoS ONE 8. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3735519/. Accessed 2013 September 10.